Compare Gilead Sciences, Inc. (GILD) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while abrdn Physical Palladium Shares ETF trades at $21 (market cap $586.03M). The key difference: Gilead Sciences, Inc. is far larger — about 311.2× abrdn Physical Palladium Shares ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| GILD | PALL | |
|---|---|---|
Market Cap | $182.40B | $586.03M |
Volume | 4,469,821 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $37.18 |
52-Week Low | $116.74 | $20.30 |
Typical Hold Time | 111 Days | 33 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
